Chronos Archive seal
The Human Record

Benjamin Franklin

Case HR-EN004 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
January 17, 1706 – April 17, 1790
Synthetic DOB
1950-01-17
Index visit
2026-03-02 at age 76
Synthetic MRN
HR-EN004-SYN

Teaching objective: Manage recurrent gout in a 76-year-old man with stage 3a chronic kidney disease by the 2020 ACR treat-to-target approach (allopurinol started low and titrated to a serum urate below 6 mg/dL, colchicine prophylaxis, a thiazide replaced by losartan), and evaluate a bladder stone with imaging, cystoscopy, and flow studies, treating its outlet-obstruction cause and preventing uric acid stones with fluids, urinary alkalinization, and metabolic testing, while following the CMID kidney, blood pressure, and prostate schedules.

Historical timeline

DateEventClaims
January 17, 1706 (January 6, 1706, Old Style)Born in Boston.CLM-0001
1724Works as a compositor in London and feels pain in the bones of his hand over heated type.CLM-0002
February 1727 (1726/7 Old Style)Pleurisy that very nearly carried him off.CLM-0010
1735Severe pleurisy ending in an abscess of the left lung.CLM-0011
October 22, 1780Writes the Dialogue between Franklin and the Gout during a gout attack.CLM-0005
March 12, 1781Writes to Congress that a long and severe fit of gout the previous winter has shaken him.CLM-0006
About 1781First symptoms of the calculous complaint (bladder stone).CLM-0007
May 23, 1785Writes that he is subject to the gout and the stone.CLM-0008
April 15, 1787Writes that the stone has increased.CLM-0009
1789 to 1790Confined chiefly to bed by the stone for his last twelve months, taking laudanum for the worst pain.CLM-0014
April 17, 1790Died in Philadelphia after a febrile chest illness.CLM-0015

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Benjamin Franklin was born in Boston on January 17, 1706 (New Style); an editor's note to his autobiography gives the date as Sunday, January 6, old style, 1706, in a house on Milk Street. confirmed Benjamin Franklin (biography) supports
Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports
D In a letter of July 31, 1786, Franklin recalled that in 1724, as a compositor at Palmer's printing house in London, he sometimes heated his case of type before the fire to warm his hands, until an old workman warned him he might lose the use of his hands, and that he had felt a kind of obscure pain in the bones of his hand when working over very hot type.
His own account of occupational exposure to heated type metal, which contains lead.
confirmed The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 2. London; 1806 supports
D A 2008 review of his medical history by Finger and Hagemann concluded that he suffered repeated attacks of gout and a large bladder stone, which caused considerable pain and markedly decreased his mobility. confirmed Finger S, Hagemann IS. Benjamin Franklin's risk factors for gout and stones: from genes and diet to possible lead poisoning. Proc Am Philos Soc. 2008;152(2):189-206 supports
The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports
Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports
R The same review argues that several factors that raise uric acid converged in him, including sex, genetics, diet, drinking, advanced age, psoriasis, and possible lead poisoning from lead exposure.
A retrospective interpretation; lead poisoning is not documented as a diagnosis in his lifetime.
possible Finger S, Hagemann IS. Benjamin Franklin's risk factors for gout and stones: from genes and diet to possible lead poisoning. Proc Am Philos Soc. 2008;152(2):189-206 supports
D Franklin wrote the Dialogue between Franklin and the Gout, headed Midnight, October 22, 1780, in which the Gout tells him he has eaten and drunk too freely and indulged his indolence; a 2023 rheumatology review states that he woke with a gout attack that night. confirmed The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 3. London; 1806 supports
Mikhael M, Siva C. "Dialogue Between Franklin and the Gout" Reexamined. Clin Med Res. 2023;21(4):196-200. doi:10.3121/cmr.2023.1833 supports
D In a letter from Passy dated March 12, 1781, to Samuel Huntington, President of Congress, Franklin wrote that he had passed his seventy-fifth year and that the long and severe fit of the gout he had the last winter had shaken him exceedingly, leaving him far from his former bodily strength. confirmed Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports
D The 1806 edition of his works states that he had been little subject to disease, except an attack of the gout occasionally, until about the year 1781, when he was first attacked with symptoms of the calculous complaint, which continued during his life.
Calculous complaint means stone; his later letters identify it as the stone.
confirmed The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports
D In a letter from Passy dated May 23, 1785, to George Wheatley, Franklin agreed that the gout is bad and the stone is worse, and wrote that at fourscore he found himself subject to the gout and the stone. confirmed Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports
D Writing from Philadelphia on April 15, 1787, he said he had never had the least doubt that his malady was the stone, that it had increased but gave him no more pain than at Passy, and that he thought himself favored to have only the stone and gout; in a letter of October 24, 1788, he wrote that he was recovering from a long-continued gout. confirmed Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports
D In his autobiography Franklin wrote that at the beginning of February 1726/7 he was taken ill with a pleurisy that very nearly carried him off. confirmed Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports
D The 1806 edition of his works adds that in 1735 he had a severe pleurisy that ended in an abscess of the left lobe of his lungs, and that a second similar attack some years later left no lasting effect on his breathing. confirmed The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports
D His autobiography records that he never knew his father or mother to have any sickness but that of which they died, his father Josiah at 89 in 1744 and his mother Abiah at 85 in 1752.
The causes of death are not recorded in the source.
confirmed Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports
D Franklin wrote that in 1736 he lost a son, a boy of four, to smallpox taken in the common way, and regretted that he had not had him inoculated. confirmed Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports
D His physician's account of his last illness states that the stone had for the last twelve months confined him chiefly to his bed, and that during the most painful paroxysms he took large doses of laudanum. confirmed The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports
D About sixteen days before his death he developed a fever, then pain in the left side of the chest with cough and labored breathing; an abscess in his lungs burst, and he died in Philadelphia at about eleven at night on April 17, 1790, aged 84.
The contemporary account is reported as written; the modern cause cannot be determined.
confirmed The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports
Benjamin Franklin (biography) supports
R A 2023 review describes him as overweight and as probably having had consequences of the metabolic syndrome, including gout.
Retrospective interpretation; no measured weight is used.
possible Mikhael M, Siva C. "Dialogue Between Franklin and the Gout" Reexamined. Clin Med Res. 2023;21(4):196-200. doi:10.3121/cmr.2023.1833 supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout active confirmed both_with_link CLM-0003, CLM-0005, CLM-0006
S Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone resolved confirmed both_with_link CLM-0003, CLM-0007, CLM-0009
S Chronic kidney disease stage G3a A1 active confirmed active
S Essential hypertension active confirmed active
S Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resection active confirmed active
S Acute gout flare of the left knee, crystal-proven, during urate-lowering titration; resolved resolved confirmed active CLM-0003

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-03-02 Urate [Mass/volume] in Serum or Plasma 9.1 mg/dL (high)
Reference 3.5-7.2 mg/dL
http://loinc.org · 3084-1
S 2026-03-02 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-03-02 Potassium [Moles/volume] in Serum or Plasma 4.1 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-02 Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-03-02 Urea nitrogen [Mass/volume] in Serum or Plasma 22 mg/dL
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-03-02 Creatinine [Mass/volume] in Serum or Plasma 1.36 mg/dL (high)
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-03-02 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 54 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-02 Glucose [Mass/volume] in Serum or Plasma 98 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-02 Calcium [Mass/volume] in Serum or Plasma 9.5 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-03-02 Phosphate [Mass/volume] in Serum or Plasma 3.4 mg/dL
Reference 2.5-4.5 mg/dL
http://loinc.org · 2777-1
S 2026-03-02 Parathyrin.intact [Mass/volume] in Serum or Plasma 52 pg/mL
Reference 15-65 pg/mL
http://loinc.org · 2731-8
S 2026-03-02 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-03-02 Hemoglobin [Mass/volume] in Blood 14.2 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-03-02 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-03-02 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 mg/dL (high)
Reference <=99 mg/dL
http://loinc.org · 13457-7
S 2026-03-02 Hemoglobin A1c/Hemoglobin.total in Blood 5.6%
Reference <=5.6%
http://loinc.org · 4548-4
S 2026-03-02 Albumin/Creatinine [Mass Ratio] in Urine 18 mg/g
Reference <=30 mg/g
http://loinc.org · 9318-7
S 2026-03-02 pH of Urine 5.2 [pH]
Reference 4.5-8 [pH]
http://loinc.org · 2756-5
S 2026-03-02 Erythrocytes [#/area] in Urine sediment by Microscopy high power field 12 /[HPF] (high)
Reference <=2 /[HPF]
http://loinc.org · 13945-1
S 2026-03-02 Lead [Mass/volume] in Blood 3.1 ug/dL
Reference <=3.5 ug/dL
http://loinc.org · 5671-3
S 2026-03-02 International Prostate Symptom Score [IPSS] 16 http://loinc.org · 80976-4
S 2026-03-02 Kidney failure 2-year risk [Likelihood] by KFRE 0.2% http://loinc.org · 85624-5
S 2026-03-02 Kidney failure 5-year risk [Likelihood] by KFRE 0.6% http://loinc.org · 85625-2
S 2026-03-30 Urate [Mass/volume] in Serum or Plasma 7.6 mg/dL (high)
Reference 3.5-7.2 mg/dL
http://loinc.org · 3084-1
S 2026-03-30 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-03-30 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-30 Carbon dioxide, total [Moles/volume] in Serum or Plasma 24 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-03-30 Urea nitrogen [Mass/volume] in Serum or Plasma 21 mg/dL
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-03-30 Creatinine [Mass/volume] in Serum or Plasma 1.34 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-03-30 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 55 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-30 Glucose [Mass/volume] in Serum or Plasma 96 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-30 US Urinary bladder Volume post void 160 mL (high)
Reference <=100 mL
http://loinc.org · 98856-8
S 2026-03-30 Maximum Urine flow by Uroflowmetry 8.5 mL/s (low)
Reference >=10 mL/s
http://loinc.org · 80519-2
S 2026-03-30 International Prostate Symptom Score [IPSS] 16 http://loinc.org · 80976-4
S 2026-05-18 Urate [Mass/volume] in Serum or Plasma 6.4 mg/dL
Reference 3.5-7.2 mg/dL
http://loinc.org · 3084-1
S 2026-05-18 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-05-18 Potassium [Moles/volume] in Serum or Plasma 4.5 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-05-18 Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-05-18 Urea nitrogen [Mass/volume] in Serum or Plasma 20 mg/dL
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-05-18 Creatinine [Mass/volume] in Serum or Plasma 1.31 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-05-18 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 56 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-05-18 Glucose [Mass/volume] in Serum or Plasma 95 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-05-18 pH of Urine 5.3 [pH]
Reference 4.5-8 [pH]
http://loinc.org · 2756-5
S 2026-05-18 Erythrocytes [#/area] in Urine sediment by Microscopy high power field 1 /[HPF]
Reference <=2 /[HPF]
http://loinc.org · 13945-1
S 2026-05-18 Volume of 24 hour Urine 1.45 L/(24.h) (low)
Reference At least 2.5 L a day for stone prevention
http://loinc.org · 3167-4
S 2026-05-18 Urate [Mass/time] in 24 hour Urine 840 mg/(24.h) (high)
Reference <=800 mg/(24.h)
http://loinc.org · 3087-4
S 2026-05-18 Citrate [Mass/time] in 24 hour Urine 410 mg/(24.h)
Reference >=320 mg/(24.h)
http://loinc.org · 6687-8
S 2026-05-18 Calcium [Mass/time] in 24 hour Urine 180 mg/(24.h)
Reference <=250 mg/(24.h)
http://loinc.org · 6874-2
S 2026-05-18 US Urinary bladder Volume post void 35 mL
Reference <=100 mL
http://loinc.org · 98856-8
S 2026-05-18 International Prostate Symptom Score [IPSS] 6 http://loinc.org · 80976-4
S 2026-09-14 Urate [Mass/volume] in Serum or Plasma 5.4 mg/dL
Reference 3.5-7.2 mg/dL
http://loinc.org · 3084-1
S 2026-09-14 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-09-14 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-09-14 Carbon dioxide, total [Moles/volume] in Serum or Plasma 26 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-09-14 Urea nitrogen [Mass/volume] in Serum or Plasma 21 mg/dL
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-09-14 Creatinine [Mass/volume] in Serum or Plasma 1.32 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-09-14 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 56 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-09-14 Glucose [Mass/volume] in Serum or Plasma 97 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-09-14 pH of Urine 6.3 [pH]
Reference 4.5-8 [pH]
http://loinc.org · 2756-5
S 2026-09-14 US Urinary bladder Volume post void 30 mL
Reference <=100 mL
http://loinc.org · 98856-8
S 2026-09-14 International Prostate Symptom Score [IPSS] 5 http://loinc.org · 80976-4
S 2026-07-06 Urate [Mass/volume] in Serum or Plasma 5.9 mg/dL
Reference 3.5-7.2 mg/dL
http://loinc.org · 3084-1
S 2026-07-06 Potassium [Moles/volume] in Serum or Plasma 4.7 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-07-06 Creatinine [Mass/volume] in Serum or Plasma 1.33 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-07-06 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 55 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-07-06 Glucose [Mass/volume] in Serum or Plasma 104 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-10-19 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2026-10-19 Total score [Mini-Cog] 5 http://loinc.org · 72233-0
S 2026-10-19 Total score [AUDIT-C] 4 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-03-02Body height175 cm8302-2S
2026-03-02Body weight96 kg29463-7S
2026-03-02Body mass index (BMI) [Ratio]31.3 kg/m239156-5S
2026-03-02Systolic blood pressure148 mm[Hg]8480-6S
2026-03-02Diastolic blood pressure86 mm[Hg]8462-4S
2026-03-02Heart rate74 /min8867-4S
2026-03-02Respiratory rate16 /min9279-1S
2026-03-02Body temperature36.7 Cel8310-5S
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-03-30Body height175 cm8302-2S
2026-03-30Body weight95.4 kg29463-7S
2026-03-30Body mass index (BMI) [Ratio]31.2 kg/m239156-5S
2026-03-30Systolic blood pressure138 mm[Hg]8480-6S
2026-03-30Diastolic blood pressure80 mm[Hg]8462-4S
2026-03-30Heart rate70 /min8867-4S
2026-03-30Respiratory rate16 /min9279-1S
2026-03-30Body temperature36.6 Cel8310-5S
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-05-18Body height175 cm8302-2S
2026-05-18Body weight94.6 kg29463-7S
2026-05-18Body mass index (BMI) [Ratio]30.9 kg/m239156-5S
2026-05-18Systolic blood pressure132 mm[Hg]8480-6S
2026-05-18Diastolic blood pressure78 mm[Hg]8462-4S
2026-05-18Heart rate72 /min8867-4S
2026-05-18Respiratory rate16 /min9279-1S
2026-05-18Body temperature36.7 Cel8310-5S
2026-05-18Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-09-14Body height175 cm8302-2S
2026-09-14Body weight93.2 kg29463-7S
2026-09-14Body mass index (BMI) [Ratio]30.4 kg/m239156-5S
2026-09-14Systolic blood pressure128 mm[Hg]8480-6S
2026-09-14Diastolic blood pressure76 mm[Hg]8462-4S
2026-09-14Heart rate68 /min8867-4S
2026-09-14Respiratory rate14 /min9279-1S
2026-09-14Body temperature36.6 Cel8310-5S
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-07-06Body height175 cm8302-2S
2026-07-06Body weight94 kg29463-7S
2026-07-06Body mass index (BMI) [Ratio]30.7 kg/m239156-5S
2026-07-06Systolic blood pressure136 mm[Hg]8480-6S
2026-07-06Diastolic blood pressure80 mm[Hg]8462-4S
2026-07-06Heart rate84 /min8867-4S
2026-07-06Respiratory rate16 /min9279-1S
2026-07-06Body temperature37.7 Cel8310-5S
2026-07-06Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-10-19Body height175 cm8302-2S
2026-10-19Body weight93 kg29463-7S
2026-10-19Body mass index (BMI) [Ratio]30.4 kg/m239156-5S
2026-10-19Systolic blood pressure126 mm[Hg]8480-6S
2026-10-19Diastolic blood pressure74 mm[Hg]8462-4S
2026-10-19Heart rate66 /min8867-4S
2026-10-19Respiratory rate14 /min9279-1S
2026-10-19Body temperature36.6 Cel8310-5S
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Serum urate below 6 mg/dL on allopurinol by the six-month review2026-09-14completedSerum urate 5.4 mg/dL on allopurinol 300 mg
Bladder stone removed and comfortable voiding with a normal post-void residual2026-05-18completedStone removed; IPSS from 16 to 6; residual 35 mL
No gout flare for six months after starting urate-lowering therapy2026-09-14activeNot met: one knee flare in July while urate was still above target; none since
Blood pressure below 130/80 without dizziness2026-09-14completed128/76 mmHg on losartan
Urine output of at least 2.5 L a day and urine pH of 6.0 to 6.52026-09-14activeUrine pH 6.3 on potassium citrate; home measuring jug shows about 2.3 L a day

Interventions

InterventionStatusGuideline
Start allopurinol 100 mg daily and raise it by 100 mg every 2 to 5 weeks until serum urate is below 6 mg/dL; HLA-B*58:01 testing is not indicated, because he is not of Southeast Asian or African ancestrycompletedGL-ACR-GOUT-2020
Colchicine 0.6 mg daily for three to six months as flare prophylaxis; treat flares with a short prednisone course or extra colchicine, and avoid NSAIDs because of chronic kidney diseasecompletedGL-ACR-GOUT-2020, GL-CMID-2026
Replace hydrochlorothiazide with losartan, which lowers blood pressure and slightly lowers urate; check potassium and creatinine 2 to 4 weeks after startingcompletedGL-ACR-GOUT-2020, GL-CMID-2026, GL-ACC-HTN-2017
Urology referral to confirm and remove the bladder stone, look for bladder outlet obstruction and other causes of hematuria, and advise on stone preventioncompletedGL-AUA-STONE, GL-EAU-UROLITH, GL-AUA-BPH
Uric acid stone prevention: fluids for a urine output of at least 2.5 L a day, potassium citrate to a urine pH of 6.0 to 6.5, stone analysis, and a 24-hour urine collectioncompletedGL-AUA-STONE, GL-EAU-UROLITH
CMID kidney and blood pressure monitoring: blood pressure every visit; eGFR and urine albumin yearly at G3a A1; calcium, phosphate, and PTH at baseline; hemoglobin and the kidney failure risk equation yearly; statin for age over 50 with eGFR below 60; medication review for NSAIDs every visitcompletedGL-CMID-2026, GL-KDIGO-CKD-2024
Limit alcohol, especially beer and spirits, and purine-rich meat, organ meat, and shellfish; avoid sugar-sweetened drinks; aim for gradual weight loss and daily walkingcompletedGL-ACR-GOUT-2020

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 Project Gutenberg (eBook 48136) primary
SRC-0002 Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers Project Gutenberg (eBook 40236) primary
SRC-0003 The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 2. London; 1806 Project Gutenberg (eBook 48137) primary
SRC-0004 The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 3. London; 1806 Project Gutenberg (eBook 48138) primary
SRC-0005 Franklin B. Autobiography of Benjamin Franklin (edited, with notes) Project Gutenberg (eBook 20203) primary
SRC-0006 HISTMED Master Roster v3 The Human Record project other
SRC-0007 Benjamin Franklin (biography) American Battlefield Trust other
SRC-0008 Finger S, Hagemann IS. Benjamin Franklin's risk factors for gout and stones: from genes and diet to possible lead poisoning. Proc Am Philos Soc. 2008;152(2):189-206 PubMed (PMID 19244863) scholarly
SRC-0009 Mikhael M, Siva C. "Dialogue Between Franklin and the Gout" Reexamined. Clin Med Res. 2023;21(4):196-200. doi:10.3121/cmr.2023.1833 PubMed (PMID 38296638) scholarly

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check allopurinol titration in stage 3a CKD, colchicine with atorvastatin, potassium citrate with losartan, and the two titration and potassium-check deviations recorded.
provenance reviewnot_startedGutenberg editions of his letters, works, and autobiography, two PubMed abstracts, and an American Battlefield Trust biography logged; Founders Online could not be fetched (bot challenge). Lead poisoning is graded R, possible.
safe messaging reviewnot_startedNo behavioral-health content; laudanum use in his last year is recorded only as historical fact; death recorded without graphic detail.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.